ROS1 and neoplasm: ROS1+ NSCLC tumors made up of 78.8% of the ROS1+ solid tumors, followed by ROS1+ GBM (6.9%), and ROS1+ breast cancer (2.7%) followed by 1–3 cases of ROS1 fusions among the the rest of the 13 tumor types (Fig. 1A body figure, Fig. 1B pie chart).